



PATENT
ATTORNEY DOCKET NO. 50291/004002

Certificate of Mailing: Date of Deposit: March 7, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jennifer M. Schupp

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert Chalifour et al.	Art Unit:	1614
Serial No.:	10/825,958	Examiner:	Not Yet Assigned
Filed:	April 16, 2004	Customer No.:	21559
Title:	Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 09/724,842, which was filed on November 28, 2000. The references listed on the enclosed Form PTO-1449 were submitted to and/or cited by the

Office in the prior application and, therefore, copies of these references are not provided for this application.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: March 7, 2005

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50291/004002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/825,958
		Applicant Robert Chalifour et al.
		Filing Date April 16, 2004
		Group 1614
		IDS Filed March 7, 2005
(37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,116,768	09/26/1978	Isowa et al.			
	5,002,872	03/26/1991	Gross			
	5,470,951	11/28/1995	Roberts			
	5,514,548	05/07/1996	Krebber et al.			
	5,652,334	07/29/1997	Roberts			
	5,688,651	11/18/1997	Solomon			
	5,721,130	02/24/1998	Seubert et al.			
	5,753,624	05/19/1998	McMichael et al.			
	5,837,672	11/17/1998	Schenk et al.			
	5,851,996	12/22/1998	Kline			
	5,854,204	12/29/1998	Findeis et al.			
	5,869,093	02/09/1999	Weiner et al.			
	5,891,991	04/06/1999	Wasco et al.			
	5,985,242	11/16/1999	Findeis et al.			
	6,261,569	07/17/2001	Comis et al.			
	10/895,646	Filed 07/21/2004	Chalifour et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	94/05311	03/17/1994	WO			
	95/05393	02/23/1995	WO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/004002 10/825,958 Robert Chalifour et al. April 16, 2004 1614 March 7, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

	95/05849	03/02/1995	WO			
	95/08999	04/06/1995	WO			
	95/12815	05/11/1995	WO			
	95/23166	08/31/1995	WO			
	95/31996	11/30/1995	WO			
	96/13583	05/09/1996	WO			
	96/28471	09/19/1996	WO			
	96/37621	11/28/1996	WO			
	97/08320	03/06/1997	WO			
	97/21728	06/19/1997	WO			
	97/32017	09/04/1997	WO			
	98/02462	01/22/1998	WO			
	98/05350	02/12/1998	WO			
	98/08868	03/05/1998	WO			
	98/22120	05/28/1998	WO			
	99/06587	02/11/1999	WO			
	99/27944	06/10/1999	WO			
	99/27949	06/10/1999	WO			
	99/58564	11/18/1999	WO			
	99/60021	11/25/1999	WO			
	99/60024	11/25/1999	WO			
	00/20027	04/13/2000	WO			
	00/26238	05/11/2000	WO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50291/004002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/825,958	
		Applicant Robert Chalifour et al.	
		Filing Date April 16, 2004	
		Group 1614	
		IDS Filed March 7, 2005	
(37 C.F.R. § 1.98(b))			

	00/43039	07/27/2000	WO			
	00/68263	11/16/2000	WO			
	0752886 B1	01/28/1998	EP			
	199870091	07/30/1998	AU			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Alberts, Molecular Biology of the Cell, Garland Publishing, page 54, 1989.
	Bard et al., "Peripherally Administered Antibodies Against Amyloid Beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nat. Med. 6(8):916-919, 2000.
	Benkirane et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," J. Biol. Chem. 268(23):26279-26285, 1993.
	DeMattos et al., "Peripheral Anti-ABeta Antibody Alters CNS and Plasma ABeta Clearance and Decreases Brain ABeta Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA [epub ahead of print], 2001.
	Findeis et al., "Modified Peptide Inhibitors of Amyloid Beta-Peptide Polymerization," Biochemistry 38:6791-6800, 1999.
	Flood et al., "Topography of a Binding Site for Small Amnestic Peptides Deduced from Structure-Activity Studies: Relation to Amnestic Affect of Amyloid Beta Protein," Proc. Natl. Acad. Sci. USA 91:380-384, 1994.
	Frenkel, "Generation of Auto-Antibodies Towards Alzheimer's Disease Vaccination," Vaccine 19(17-19):2615-2619, 2001.
	Frenkel, "Immunization Against Alzheimer's Beta-Amyloid Plaques Via EFRH Phage Administration," Proc. Natl. Acad. Sci. USA 97(21):11455-11459, 2000.
	Giulian, "The HHQK Domain of Beta-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," J. Biol. Chem. 273(45):29719-29726, 1998.
	Morgan et al., "A Beta Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," Nature 408(6815):982-985, 2000.
	Pearson et al., "Beta Peptide Immunization Reduces Behavioral Impairment and Plaques in a Model of Alzheimer's Disease," Nature 408(6815):979-982, 2000.
	Schenk et al., "Immunization with Amyloid-Beta Attenuates Alzheimer's-Disease-Like Pathology in the PDAPP Mouse," Nature 400(6740):173-177, 1999.
	Sela et al., "Different Roles of D-Amino Acids in Immune Phenomena," FASEB J. 11(6):449-456, 1997.
	Soto et al., "Inhibition of Alzheimer's Amyloidosis by Peptides that Prevent Beta-Sheet Conformation," Biochem. Biophys. Res. Comm. 226(3):672-680, 1996.
	Tjernberg et al., "Arrest of Beta-Amyloid Fibril Formation by a Pentapeptide Ligand," J. Biol. Chem. 271(15):8545-8548, 1996.
	Tjernberg et al., "Controlling Amyloid Beta-Peptide Fibril Formation with Protease-Stable Ligands," J. Biol. Chem. 272(19):12601-12605, 1997.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50291/004002
		Serial No.	10/825,958
		Applicant	Robert Chalifour et al.
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	April 16, 2004
		Group	1614
(37 C.F.R. § 1.98(b))		IDS Filed	March 7, 2005

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	